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The main aims for preparative regimens
in BMT/PBPCT are malignant cell eradication
and/or immunosupresion to facilitate engraftment.
TBI is used in concert with cyclophospamide (Cy)
to increase activity.
In our Unit two TBI + Cy conditioned allo~
transplantations ~ (1) BMT and (2) PBPCT ~ have
been performed. Patients ~ (1) 7 years and (2) 10
years old, males, suffering from: (1 )ALL ~ second
and (2)ALL ~ fourth remission, received transplant
material from HLA identical siblings. Transplant
preparative regimens consisted of TBI (Co~60 +
electrons 6 and 9 MeV: 12~16 Gy. performed in
Greatpoland Cancer Centre, Poznan) and Cy
(200mg/kg bw). Patients received routine
decontamination for infection prevention. Heparine
for VOD and Cyclosporine + MTX for GvHD
prophylaxis. Treatment related toxicity was judged
accordind to WHO scale, standard criteria were
used for GvHD grading.
Both patients were Hepatitis B virus positive, patient
(2) was also HCV + before treatment.
Hematological recovery was observed in both
patient (1) 13 and (2) 10 days after transplantation.
Toxicity in patient (1) was WHO-1 for the liver and
WHO-1 for kidneys. There was no skin or mucosal
toxicity. Patient (2) had WHO~2 GIT mucosa and
WHO~3 liver toxicities on day +15. No skin toxicity
was observed. On day +16 patient(2) rapidly
developed signs of pulmonary complications further
followed by CNS involvement. He required artificial
ventilation. No aGvHD observed. Patient died on
day +31. Patient (1) is alive and well +36 days
after transplantation. aGvHD grade I (skin) was
observed on day +25 after transplantation and
responded well to glukokorticosteroid therapy
(2mg/kg for 5 days).
The post~transplant history of these two
cases reflects on possible complications
of BMT/PBPCT with TBI.
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Surgery is the oldest and the most
important treatment for cancer (75 - 80% patients
presenting with cancer). Surgery is the simple,
safe and the only treatment that could cure most
patients (20% from 50% of 5 year survival).
Unfortunately, when patients with solid
tumors present to the physician for the first time,
about 50% already have micrometastases
byeond the primary site.
The magnitude of surgical resection
is modified by the use of adjuvant treatment
modalities (radiotherapy, chemotherapy, biologic
therapy - 50% of 5 year survival).
The role of surgery in the combinated
treatment of cancer patients can be divided into a
few separate areas:
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* Definitive surgical treatment of primary cancer
(operatio m. Halsted, m. Miles)
* Cytoreductive surgery (to reduce the bulk
of residual disease)
* Surgical resection of metastatic disease (40%
of 5 year survival in pulmonary and hepatic
metastases)
* Surgery for palliation and oncologic
emergencies (the treatment of exsanguinating
hemorrhage, perforation, the relief of pain)
* Diagnostic surgery for exact histologic diagnosis
and precise staging when planning
* Surgery in cancer prevention (carcinoma
"in situ", treatment to prevent SUbsequent
cancers)
Slides show the role of surgery in
combinated treatment of cancers.
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